Acurex Biosciences

Acurex Biosciences is a pharmaceutical company with a mission to halt major neurodegenerative diseases driven by impaired mitophagy, starting with Parkinsons disease (PD). A large body of evidence now supports that impairment of mitophagy, the normal process by which cells dispose of dysfunctional mitochondria, plays a significant role in the pathogenesis of PD and other diseases. Acurexs platform and founding intellectual property are based on a Stanford University breakthrough discovery enabling the identification of druggable targets responsible for defects in mitophagy. Acurexs platform has generated two oral small-molecule therapeutic programs that cross the BBB, reactivate mitophagy, and protect PD patient-derived neurons. Acurexs lead program will begin IND-enabling studies in 2H 2023, and the second program to a distinct target is in lead selection. Acurexs clinical development plan leverages its proprietary biomarker of mitophagy that can be measured in the periphery and...